Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
March 03, 2025 16:01 ET
|
Biodesix, Inc.
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and...
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie,...
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
February 18, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth...
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
January 10, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter...
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
January 07, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical...
Biodesix Announces Third Quarter 2024 Results and Highlights
November 01, 2024 06:00 ET
|
Biodesix, Inc.
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and...
Biodesix to Participate in Three Investor Conferences in November
October 29, 2024 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive...
Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR
March 26, 2019 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
November 12, 2018 09:00 ET
|
Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...
Biodesix Advances ORACLE Registry for Lung Nodule Cancer Test
October 30, 2018 08:27 ET
|
Biodesix, Inc.
Noninvasive Test to Rule Out Cancer Expected to Lower Patient Anxiety and Costs BOULDER, Colo., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Biodesix® today provided an update on the Observational Registry...